Shao, Hui

Newer glucose‐lowering drugs and risk of dementia: A systematic review and meta‐analysis of observational studies

Tang, H., Shao, H., Shaaban, C. E., Yang, K., Brown, J., Anton, S., Wu, Y., Bress, A., Donahoo, W. T., DeKosky, S. T., et al. (2023) · Journal of the American Geriatrics Society

Diabetes Treatment and ManagementDementia and Cognitive Impairment Research

Cited by 106

Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity

Li, P., Varghese, J. S., Shah, M. K., Galindo, R. J., Pasquel, F. J., Ali, M. K., & Shao, H. (2025) · JAMA Network Open

Diabetes Treatment and ManagementBariatric Surgery and Outcomes

Cited by 43

Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes: A Target Trial Emulation Study

Tang, H., Lu, Y., Donahoo, W. T., Shao, H., Shi, L., Fonseca, V. A., Guo, Y., Bian, J., & Guo, J. (2024) · Annals of Internal Medicine

Diabetes Treatment and ManagementSuicide and Self-Harm Studies

Cited by 40

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial

Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 39

A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes.

Yoshida, Y., Cheng, X., Shao, H., Fonseca, V. A., & Shi, L. (2020) · Current Diabetes Reports

Diabetes Treatment and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 39

Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review

Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid

Diabetes Treatment and ManagementThyroid Cancer Diagnosis and Treatment

Cited by 37

Trajectories of Short Physical Performance Battery Are Strongly Associated with Future Major Mobility Disability: Results from the LIFE Study

Brown, J. D., Lo-Ciganic, W.-H., Shao, H., Pahor, M., & Manini, T. M. (2020) · Journal of Clinical Medicine

Frailty in Older AdultsBalance, Gait, and Falls Prevention

Cited by 20

Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes

Chen, W.-H., Li, Y., Yang, L., Allen, J. M., Shao, H., Donahoo, W. T., Billelo, L., Hu, X., Shenkman, E. A., Bian, J., et al. (2024) · PLOS ONE

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 17

Socioeconomic factors play a more important role than clinical needs in the use of SGLT2 inhibitors and GLP-1 receptor agonists in people with type 2 diabetes.

Shao, H., Li, P., Guo, J., Fonseca, V., Shi, L., & Zhang, P. (2022) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 13

Association between first-line antidepressant use and risk of dementia in older adults: a retrospective cohort study

Wang, G. H.-M., Chen, W.-H., Chang, S.-H., Zhang, T., Shao, H., Guo, J., & Lo-Ciganic, W.-H. (2023) · BMC Geriatrics

Dementia and Cognitive Impairment ResearchTreatment of Major Depression

Cited by 13

Does the encounter type matter when defining diabetes complications in electronic health records?

Hong, D., Shen, Y., Monnette, A., Liu, S., Shao, H., Nauman, E., Price-Haywood, E., Hu, G., & Shi, L. (2020) · Medical Care

Medical Coding and Health InformationMachine Learning in Healthcare

Cited by 4